Edmond Mok

Edmond Mok has a long and varied career in finance. Edmond began their career in 2014 as the Head of Finance at Afferent Pharmaceuticals, a position they held until the company was acquired by Merck in 2016. Edmond then served as the Vice President of Finance (Consultant) for Applied Molecular Transport from 2015 to 2017. In 2017, they became the Interim CFO for R2M Pharma, Inc. and also founded LaMok Consulting LLC, where they provided financial consulting services (VP Finance/CFO levels) for early stage through IPO biotech companies. Edmond also served as Vice President of Finance (Consultant) for Neurona Therapeutics, Attenua Inc. (acquired by CODA), Proneurotech (now Nura Bio), Convelo Therapeutics, and MapKure LLC. Edmond currently serves as Vice President of Finance (Consultant) for Curasen Therapeutics, Inc.

Edmond Mok attended the University of California, Berkeley from 1991 to 1993, where they earned a Bachelor of Arts in Interdisciplinary Studies.